Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation, By Type
6.1 Bi0logical
6.2 Non-Biological
Chapter 7 Market Segmentation, By Top-Selling Drugs
7.1 Sprycel
7.2 Cyramza
7.3 Ofev
7.4 Yervoy
7.5 Obeticholic Acid
7.6 Kyprolis
7.7 Advate
7.8 Gazyva
7.9 Alimta
7.10 Pomalyst
7.11 Tasigna
7.12 Esbriet
7.13 Imbruvica
7.14 Orkambi
7.15 Keytruda
7.16 Soliris
7.17 Opdivo
7.18 Revlimid
7.19 Rituxan
7.20 Others
Chapter 8 Market Segmentation, By Disease Type
8.1 Oncologic Diseases
8.2 Metabolic Diseases
8.3 Hematologic and Immunologic Diseases
8.4 Infectious Diseases
8.5 Others
Chapter 9 Market Segmentation, By Indication
9.1 Non-Hodgkins Lymphoma
9.2 Acute Myeloid Leukemia
9.3 Cystic Fibrosis
9.4 Glioma
9.5 Pancreatic Cancer
9.6 Ovarian Cancer
9.7 Multiple Myeloma
9.8 Duchenne Muscular Dystrophy
9.9 Graft vs. Host Disease
9.10 Renal Cell Carcinoma
9.11 Others
Chapter 10 Market Segmentation, By Geography
10.1 North America
10.1.1 Introduction
10.1.2 United States
10.1.3 Canada
10.1.4 Mexico
10.1.5 Others
10.2 Europe
10.2.1 Introduction
10.2.2 U.K
10.2.3 Spain
10.2.4 Italy
10.2.5 France
10.2.6 Russia
10.2.7 Others
10.3 Asia-Pacific
10.3.1 Introduction
10.3.2 China
10.3.3 India
10.3.4 Japan
10.3.5 Australia
10.3.6 Others
10.4 South America
10.4.1 Introduction
10.4.2 Brazil
10.4.3 Argentina
10.4.4 Others
10.5 The Middle East & Africa
10.5.1 Introduction
10.5.2 South Africa
10.5.3 Others
Chapter 11 Competitive Landscape
11.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
11.2 Market Share Analysis
11.3 Strategies Adopted By Top Companies
Chapter 12 Company Profiles
12.1. Vertex Pharmaceuticals
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Benchmarking
12.1.4. Strategic Initiative
12.2. AbbVie
12.3. Merck
12.4. Johnson & Johnson
12.5. Sanofi
12.6. Alexion
12.7. Bristol Myers Squibb
12.8. Roche
12.9. Pfizer
12.10. Novartis
12.11. Celgene
12.12. Bayer
12.13. GlaxoSmithKline PLC
12.14. Aegerion Pharmaceuticals, Inc
12.15. Daiichi Sankyo Company Limited
Chapter 13 Market Estimates and Forecast
13.1 Market Estimates and Forecast 2018-2024(USD Million)
13.1.1 Market Estimation and Forecast by Material Type2018-2024 (USD Million)
13.1.2 Market Estimates and Forecast by Geography 2018-2024 (USD Million)
Chapter 14 Market Insights
14.1 Insights of Industry Experts
14.2 Analyst Opinion (Market Understanding)
14.3 Investment Opportunities
Chapter 15 Appendix
15.1 List of Tables
15.2 List of Figures
